PharmiWeb.com - Global Pharma News & Resources
19-Feb-2021

Nanoscale Virus Trap Molecule Market 2019 | Size, Merger and Share | By Products, Applications and End Users Overview Forecast to 2026

Global Nanoscale Virus Trap Molecule Market – Insights

Nanotechnology is an emerging field that finds application in various sectors including the healthcare sector. Use of nanotechnology can facilitate development of targeted therapies and tools that are effective, safe, and cheaper. Some of the developments in nanotechnology include, Quantum dots that can enhance biological imaging for medical diagnostics, antibody-nanoparticle complex for early diagnosis of atherosclerosis, use of nanoscale components in molecular imaging, and regeneration or spurring the growth of nerve cells.

Request for the trending sample of this report: https://www.coherentmarketinsights.com/insight/request-sample/44

The Virus ‘trap’ Nanoparticle

Nanoscale virus trap molecule is an advanced approach that aids in drug delivery. Researchers at Charles Stark Draper Laboratory, the Massachusetts Institute of Technology, the Univ. of Massachusetts Medical School, and the Univ. of Santa Barbara developed nanoparticles that act as viral ‘traps’ inside the human body. These molecules contain several carbohydrate molecules that are identical to those targeted by flu viruses. This leads binding of the viruses to the nanotraps instead of host cell. The molecules are later eliminated from the body through mucus.

The nanoscale viral trap molecule technology can find application in diagnosis of various viral diseases. Researchers at the Pennsylvania State University developed a tunable device that selectively traps viruses and detects them with 100 times better sensitivity compared to existing techniques. The device can trap virus and remove majority of the host contaminants.

Quick Buy – Nanoscale Virus Trap Molecule Market Research Report: https://www.coherentmarketinsights.com/insight/buy-now/44

The Technology is Under Research

The nanoparticle molecule is contains compounds that are naturally found in the human body, which makes the molecule safe as an inhalant, intravenous treatment, or topical solution. The approach is also cheap to produce. Such benefits of the technology can aid in its potential commercialization for the treatment of various viral infections. The technology has demonstrated positive outcome in mice. Further research can facilitate use of nanoscale viral trap molecule technology against HIV virus, Herpes Simplex Virus (HSV), and Respiratory Syncytial Virus (RSV) and various bacteria and toxins. Moreover, increasing resistance to anti-viral drugs and the need for new treatments is expected to propel demand for nanoscale virus trap molecules in the treatment of viral diseases.

However, presence of alternative therapies is expected to pose challenges to adoption of viral trap molecules. For instance, double-stranded RNA Activated Caspase Oligomerizer (DRACO) is a nanoparticle based-drug under research for detection and eradication of virally infected cells. The approach has demonstrated positive outcomes in few in-vivo and in-vitro trials against different viral strains. According to the researchers at Charles Stark Draper Laboratory, DRACO is expected to be ready for clinical trials in next three to eight years.

Conclusion

The viral trap molecule technology has several potential applications in the pharmaceutical and healthcare sector. Incensing investment in R&D and commercialization of viral trap molecule technology is expected to boost growth of the global nanoscale virus trap molecule market.

Global Nanoscale Virus Trap Molecule Market – Key Developments

Increasing R&D related to nanoscale virus trap molecule technology is expected to boost growth of the global nanoscale virus trap molecule market. For instance, in January 2019, researchers from Purdue University reported that heparan sulfate, a molecule used by Ross River virus (RRV) to help them attach to cells can prevent the virus from escaping, in the journal Virology.

To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/nanoscale-virus-trap-molecule-market-44

Increasing use of nanosponges as vehicles for antiviral drugs is also expected to propel growth of the global nanoscale virus trap molecule market. For instance, in January 2018, researchers at the University of Turin evaluated the use of cyclodextrin-based nanosponges as vehicles for antiviral drugs.

In October 2018, researchers from Far Eastern Federal University, the Russian Academy of Sciences, and Swinburne University of Technology developed a technology for trapping and chemical analysis of organic and non-organic molecules at ultra-low concentrations.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 19-Feb-2021